HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Oct
08
VOLUNTARY ANNOUNCEMENT - OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Oct
08
VOLUNTARY ANNOUNCEMENT - CPO301 RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
Oct
07
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA
Sep
30
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA
Sep
20
VOLUNTARY ANNOUNCEMENT - VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Sep
19
VOLUNTARY ANNOUNCEMENT - FURTHER SHARE BUY-BACK PLAN OF UP TO HK$5 BILLION
Sep
16
VOLUNTARY ANNOUNCEMENT - AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Sep
09
VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Sep
09
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DR. LIU YONGJUN AS EXECUTIVE PRESIDENT AND PRESIDENT OF GLOBAL RESEARCH AND DEVELOPMENT
Aug
28
VOLUNTARY ANNOUNCEMENT - DEXRAZOXANE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Aug
21
2024 INTERIM DIVIDEND
Aug
21
2024 INTERIM RESULTS
Aug
16
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2024
Aug
09
DATE OF BOARD MEETING
Aug
09
VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION
Jul
25
CONTINUING CONNECTED TRANSACTIONS - PURSUANT TO RULE 14A.60(1) OF THE LISTING RULES
Jul
11
VOLUNTARY ANNOUNCEMENT - mRNA RSV VACCINE (SYS6016) OBTAINS CLINICAL TRIAL APPROVAL
Jul
08
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jul
05
VOLUNTARY ANNOUNCEMENT - ROXADUSTAT CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Jun
28
VOLUNTARY ANNOUNCEMENT - ENLONSTOBART INJECTION OBTAINS CONDITIONAL MARKETING APPROVAL GRANTED BY NMPA
Jun
28
VOLUNTARY ANNOUNCEMENT - PALBOCICLIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jun
28
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO MASTER PURCHASE AGREEMENT
Jun
25
VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS CLINICAL TRIAL APPROVAL
Jun
12
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
11
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
07
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
04
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
03
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
03
VOLUNTARY ANNOUNCEMENT - OLAPARIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL
May
31
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
May
30
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
May
29
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
May
28
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
May
28
RETIREMENT OF EXECUTIVE DIRECTORS, APPOINTMENT OF EXECUTIVE DIRECTORS AND CHANGE OF AUTHORISED REPRESENTATIVE
May
28
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 MAY 2024
May
27
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2024
May
21
VOLUNTARY ANNOUNCEMENT - AMENDMENTS TO THE RULES OF THE RESTRICTED SHARE AWARD SCHEME
May
17
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL
May
14
DATE OF BOARD MEETING
May
14
VOLUNTARY ANNOUNCEMENT - PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Apr
26
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Apr
26
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
25
NOTICE OF ANNUAL GENERAL MEETING
Apr
24
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Apr
23
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Apr
22
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024
Apr
22
GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Apr
19
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO MASTER SALES AGREEMENT
Apr
15
EXERCISE OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME
Mar
25
VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
Mar
22
VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Mar
20
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Mar
20
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
20
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Mar
18
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Mar
14
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2023
Mar
08
DATE OF BOARD MEETING
Feb
05
VOLUNTARY ANNOUNCEMENT - INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS MARKETING APPROVAL
Jan
24
KEY FINANCIAL INFORMATION OF A SUBSIDIARY FOR THE YEAR ENDED 31 DECEMBER 2023
Jan
15
VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2024 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer